Diride-GM2
Decreases maximal postprandial plasma glucose levels by approximately 50mg./dl & HbA1C approximately 0.5-1 percentage point
Voglibose:
- Alpha-glucosidase inhibitor
- Acts as competitive inhibitor of enzymes needed to digest carbohydrates
- Specifically targets postprandial hyperglycemia, a possible independent risk factor for cardivacular complications
Modulates glycemic parameters & metabolic parameters
- Reduces HbA1C (Glycosylated haemoglobin)
- Reduces the progression of intima-media thickness
- Reduces subcutaneous adipose tissue & visceral adipose tissue
Enquiry about Diride-GM2
- Description
- Size Guide
- Reviews (0)
Description
Decreases maximal postprandial plasma glucose levels by approximately 50mg./dl & HbA1C approximately 0.5-1 percentage point
Voglibose:
- Alpha-glucosidase inhibitor
- Acts as competitive inhibitor of enzymes needed to digest carbohydrates
- Specifically targets postprandial hyperglycemia, a possible independent risk factor for cardivacular complications
Modulates glycemic parameters & metabolic parameters
- Reduces HbA1C (Glycosylated haemoglobin)
- Reduces the progression of intima-media thickness
- Reduces subcutaneous adipose tissue & visceral adipose tissue
Metformin:
- An insulin sensitizer, increases insulin action in the liver, lowering glucose production & fasting glucose levels
- It also decreases intestinal absorption of glucose & improves peripheral glucose uptake & utilization
- Improves glucose tolerance in type 2 diabetes
Glimepiride:
- A second generation sulfonylurea, lower blood glucose by stimulating release of insulin from beta cells in pancreatic islets due to increased intracellular CAMP. It is an effective for hyperglycemia in once a day dose.
| size | chest(in.) | waist(in.) | hips(in.) |
|---|---|---|---|
| XS | 34-36 | 27-29 | 34.5-36.5 |
| S | 36-38 | 29-31 | 36.5-38.5 |
| M | 38-40 | 31-33 | 38.5-40.5 |
| L | 40-42 | 33-36 | 40.5-43.5 |
| XL | 42-45 | 36-40 | 43.5-47.5 |
| XXL | 45-48 | 40-44 | 47.5-51.5 |
Reviews
There are no reviews yet.